
Kailera Therapeutics fell 51.7% from $26.00 to $12.57, behind the S&P 500's +4.2%. Its worst day was Aug 28 (−12.5%), and its low came Oct 8 at $10.00.
Apr 17, 2026 – Nov 16, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-3.65 missed the $-0.55 estimate on $0.00 revenue.
+1.6% · S&P 500 0.0%
Kailera Therapeutics shares rose 15.0%, while the S&P 500 fell 0.3%.
Story events cover the past 12 months · Times ET
+15.0% · S&P 500 −0.3%
EPS of $-1.09 missed the $-0.76 estimate on $0.00 revenue.
−3.3% · S&P 500 +0.7%
Kailera Therapeutics shares fell 12.5%, while the S&P 500 fell 0.2%.
−12.5%, the year's worst day · S&P 500 −0.2%
Kailera Therapeutics closed at its lowest level of the year, 61.5% below where the year started.
−5.0% · S&P 500 −0.4%
Kailera Therapeutics shares rose 12.8%, while the S&P 500 rose 0.3%.
+12.8% · S&P 500 +0.3%
EPS of $-0.74 beat the $-1.12 estimate on $0.00 revenue.
−4.9% · S&P 500 −4.4%
Where it ended: a close of $12.57 on Nov 16, 2026. Up next: Q4 2026 earnings on Feb 23, 2027 (EPS est. $-0.83).
Nothing in the past 12 months.
All KLRA dividend historyReplay the year: the line draws itself and stops at each of the 7 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for KLRA and SPY from Benzinga historical bars. Not investment advice.